

teriparatide 600 mcg (Forteo), teriparatide 620 mcg

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Forteo (teriparatide) 600 mcg injection pen Teriparatide 620 mcg injection pen	May be subject to quantity limit

APPROVAL CRITERIA

Initial requests for Forteo (teriparatide) 600 mcg or teriparatide 620 mcg may be approved for the following:

- I. Individual has one of the following:
 - A. Individual is a postmenopausal female with a diagnosis of osteoporosis [defined as bone mineral density (BMD) T-score in the spine, femoral neck, total hip or distal 1/3 of the radius of less than or equal to -2.5 as compared to young-adult reference population OR a clinical diagnosis based on history of a low trauma fracture (fragility fracture)] at high risk for fracture¹; **OR**
 - B. Individual is a male diagnosed with primary or hypogonadal osteoporosis [defined as BMD T-score in the spine, femoral neck, total hip or distal 1/3 of the radius of less than or equal to -2.5 as compared to young-adult reference population OR a clinical diagnosis based on a history of a low trauma fracture (fragility fracture)] at high risk for fracture¹ using to increase bone mass; **OR**
 - C. Individual has a diagnosis of osteoporosis [defined as BMD T-score in the spine, femoral neck, total hip or distal 1/3 of the radius of less than or equal to -2.5 as compared to young-adult reference population OR a clinical diagnosis based on history of low trauma fracture (fragility fracture)] associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone for at least 3 months) at high risk for fracture¹.

AND

- II. Individual is requesting Forteo – brand or teriparatide 620 mcg and has had a trial and inadequate response or intolerance generic teriparatide 600mcg (generic Forteo).
Medication samples/coupons/discount cards are excluded from consideration as a trial.;

AND

- III.
Individual meets one of the following:

- A. Individual is a postmenopausal female at very high risk for fracture as defined by one or more of the following (AACE/ACE 2020):
 - 1. Recent fracture (within the past 12 months)
 - 2. Fractures while on approved osteoporosis therapy
 - 3. Multiple fractures
 - 4. Fractures while on drugs causing skeletal harm (e.g. long-term glucocorticoids)
 - 5. Very low T-score (less than -3.0)
 - 6. High risk for falls or history of injurious falls
 - 7. Very high fracture probability by FRAX (fracture risk assessment tool) (e.g. major osteoporosis fracture >30%, hip fracture >4.5%) or other validated fracture risk algorithm;
- OR**
- B. Individual has been refractory to a prior trial of a bisphosphonate;
- OR**
- C. Individual is intolerant to or has a contraindication to a bisphosphonate as defined by:
 - 1. Hypersensitivity to TWO bisphosphonates (one of which must be alendronate); **OR**
 - 2. Inability to stand or sit upright for at least 30 minutes; **OR**
 - 3. Pre-existing gastrointestinal disorders (Barrett's esophagus, hypersecretory disorders, delayed esophageal emptying, atrophic gastritis, etc.); **OR**
 - 4. Uncorrected hypocalcemia; **OR**
 - 5. Severe renal insufficiency as defined by creatinine clearance less than 35 mL/min for alendronate agents and zoledronic acid or creatinine clearance less than 30 mL/min for risedronate and ibandronate;

AND

- IV. Individual is not using Forteo (teriparatide) 600mcg or teriparatide 620 mcg in combination with any of the following:
 - A. Prolia, Xgeva (denosumab) or Jubbonti, Wyost (denosumab-bbdz)); **OR**
 - B. Bisphosphonates: **OR**
 - C. Evista (raloxifene); **OR**
 - D. Miacalcin/Fortical (calcitonin nasal spray); **OR**
 - E. Reclast (zoledronic acid); **OR**
 - F. Tymlos (abaloparatide); **OR**
 - G. Evenity (romosozumab-aqqg); **OR**
 - H. Another teriparatide agent.

Continuation of therapy with Forteo (teriparatide) 600 mcg or teriparatide 620 mcg may be approved if the following criteria are met:

- I. There is confirmation of clinically significant response to therapy (including but not

limited to confirmation of no new fractures reduction of fractures, or no worsening vertebral fractures, or no clinically significant adverse reaction); **AND**

- II. If individual has been on therapy \geq 24 months of treatment, a repeat BMD demonstrates a stable or increase in BMD; **AND**
- III. Individual is not using Forteo (teriparatide) or Bonsity (teriparatide) in combination with any of the following:
 - A. Prolia, Xgeva (denosumab) or Jubbonti, Wyost (denosuman-bbdz);
 - B. Bisphosphonates
 - C. Evista (raloxifene)
 - D. Miacalcin/Fortical (calcitonin nasal spray)
 - E. Reclast (zoledronic acid)
 - F. Tymlos (abaloparatide);
 - G. Evenity (romosozumab-aqqg);
 - H. Another teriparatide agent.

Requests for Forteo (teriparatide) 600mcg or teriparatide 620 mcg may not be approved when the above criteria are not met and for all other indications.

Notes:

- 1. High risk for fracture is defined as the following:
 - A. History of osteoporotic fracture; or
 - B. Multiple risk factors for fractures including but not limited to: Prior low-trauma fracture as an adult, advanced age, gender, ethnicity , low bone mineral density, low body weight, family history of osteoporosis, use of glucocorticoids (daily dosage equivalent to 5mg per day or greater prednisone for at least 3 months), cigarette smoking, excessive alcohol consumption (3 or more drinks/day), secondary osteoporosis (such as, rheumatoid arthritis), early menopause, height loss or kyphosis, fall risk and low calcium intake; ; or
 - C. Failure or intolerance to other osteoporosis therapies.
- 2. A failure of other osteoporosis therapies, otherwise known as refractory disease, may be defined as a decline in BMD while on therapy ($\geq 5\%$) or a fragility fracture while on therapy.

Key References:

- 1. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. *Endocrine Practice*. 2020;26(1):1-46.
- 2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2024. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
- 3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
- 4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

5. Drug Facts and Comparisons. Facts and Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health, Inc; 2024. Updated periodically.
6. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 104, Issue 5, May 2019, Pages 1595–1622, <https://doi.org/10.1210/jc.2019-00221>.
7. Gilsenan A, Midkiff K, Harris D, et al. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1616-1626. Available at: <https://onlinelibrary.wiley.com/doi/10.1002/pds.5103> Accessed June 29, 2023..
8. Gilsenan A, Midkiff K, Harris D, et al. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J Bone Miner Res. 2021 Feb;36(2):244-251. Available at: <https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4188> Accessed June 29, 2023.
9. Shoback D, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update, The Journal of Clinical Endocrinology & Metabolism, Volume 105, Issue 3, March 2020, Pages 587-594.
10. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2024; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.